1. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome
- Author
-
Rosa Dionisio, Mario Rotondi, Rossella E. Nappi, Pasquale De Cata, Roberta Botta, Flavia Magri, Carlo Cappelli, C. Iacobello, Maurizio Castellano, and Luca Chiovato
- Subjects
endocrine system ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Endocrinology, Diabetes and Metabolism ,Thyroid ,Levothyroxine ,nutritional and metabolic diseases ,Type 2 diabetes ,medicine.disease ,Polycystic ovary ,Metformin ,Endocrinology ,medicine.anatomical_structure ,Internal medicine ,Diabetes mellitus ,medicine ,Euthyroid ,Thyroid function ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
Summary Objective Metformin is widely used for the treatment of type 2 diabetes. Growing evidence supports the beneficial effects of metformin also in patients with polycystic ovary syndrome (PCOS). It was recently reported that metformin has a TSH-lowering effect in hypothyroid patients with diabetes being treated with metformin. Design Aim of this study was to evaluate the effect of metformin treatment on the thyroid hormone profile in patients with PCOS. Patients and measurements Thirty-three patients with PCOS were specifically selected for being either treated with levothyroxine for a previous diagnosis of hypothyroidism (n = 7), untreated subclinically hypothyroid (n = 2) or euthyroid without levothyroxine treatment (n = 24) before the starting of metformin. The serum levels of TSH and FT4 were measured before and after a 4-month period of metformin therapy. Results Thyroid function parameters did not change after starting metformin therapy in euthyroid patients with PCOS. In the 9 hypothyroid patients with PCOS, the basal median serum levels of TSH (3·2 mIU/l, range = 0·4–7·1 mIU/l) significantly (P
- Published
- 2011
- Full Text
- View/download PDF